2024/25年度KP.2疫苗对老年人COVID-19住院的保护效果:加拿大魁北克检测阴性研究
在加拿大魁北克省≥60岁且符合公费接种条件的人群中开展检测阴性设计研究,评估2024/25年度KP.2疫苗对COVID-19住院的保护效果。共纳入49,949名(43%)接种者,总体疫苗有效性(VE)为34%,接种后<8周为43%,至第32周降至可忽略。
要点
- ≥60岁老年人接种KP.2疫苗后总体住院VE为34%。
- VE从接种后<8周的43%快速下降至第32周可忽略。
- 疫苗对老年人COVID-19住院的保护有意义但持续时间短。
核心结论
- 2024/25年度KP.2疫苗对≥60岁老年人COVID-19住院提供有意义但短暂的保护。
研究设计与样本
- 在加拿大魁北克省开展检测阴性设计研究,纳入2024年第42周至2025年第34周因COVID-19兼容症状在急性护理医院检测的魁北克居民。
- 通过链接疫苗、住院、慢性病和实验室行政记录评估VE,比较接种与未接种者中检测阳性 vs 阴性的比值比,调整性别、年龄、合并症、居住地和流行病学周。
主要发现
- 总体上49,949名(43%)参与者接种了疫苗。
- 分析期长达十个月,接种后中位时间为16周(四分位距9-24周)。
- 总体VE为34%,从接种后<8周的43%下降至第32周可忽略。
临床怎么用
- 提示对≥60岁老年人应关注COVID-19疫苗保护随时间快速衰减,可能需在流行季前或按推荐程序及时接种以维持对住院的保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated 2024/25 KP.2 vaccine effectiveness (VE) against COVID-19 hospitalization among adults ≥60 years old eligible for publicly-funded vaccination during fall and/or spring campaigns in the province of Quebec, Canada. We included Quebec residents tested for COVID-19-compatible symptoms in an acute-care hospital between October 13, 2024 (epi-week 2024-42) and August 23, 2025 (2025-34), linking vaccine, hospital, chronic diseases and laboratory administrative records to assess VE through test-negative design. We compared the odds of being COVID-19 test-positive versus test-negative among vaccinated versus non-vaccinated participants, adjusting for sex, age, comorbidities, place of residence, and epidemiological week. Overall, 49,949 (43%) participants were vaccinated. Over an analysis period spanning up to ten months, including median time since vaccination of 16 weeks (interquartile range 9-24 weeks), VE was 34% overall, declining from 43% <8 weeks to negligible by the 32nd week post-vaccination. Findings confirm meaningful but short-lived COVID-19 vaccine protection against hospitalization in older adults.
引用
- Carazo S, Skowronski DM, Sauvageau C, et al. 2024/25 end-of-season KP.2 vaccine effectiveness against COVID-19 hospitalization in older adults: a test-negative study in Quebec, Canada. Vaccine. 2026. PMID: 42241837. doi:10.1016/j.vaccine.2026.128786
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。